40+ results for "IoT"
CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. 2026 Maxim Growth Summit Conference Details: Format: One-on-one meetings Date: October 12
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a c
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48 – On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (
TRexBio Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting
IMC 2026: From Connectivity to Deployment at Scale, Fibocom Strengthens Its IoT Presence in India
NEW DELHI , Oct. 9, 2026 -- Fibocom (300638.SZ; 0638.HK), a leading global provider of wireless communication modules and AI solutions, presented its latest portfolio at India Mobile Congress 2026, as growing adoption of 5G, energy digitalization and connected mobility creates new demand for IoT deployment across India. At the show, Fibocom highlighted applications spanning wireless broadband, energy, vehicle and asset management. Its FWA portfolio included 5G modules as well as CPE, ODU and MiFi solutions, while smart meters, vehicle tracking devices and EV battery trackers demonstrated how cellular connectivity is moving deeper into vertical applications.
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla Biotech Inc., a subsidiary of PharmAla, have signed a distribution and licence agreement. Under the agreement, Rua will import, distribute and sell PharmAla’s pharmaceutical-grade LaNeo™ MDMA in New Zealand. The agreement follows Medsafe’s approval, on 4 September 2026, of two psy
Lakefront Receives Transparency Notification from Bank of America
Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation 1 , Lakefront received a transparency notification, from Bank of America Corporation on October 6, 2026. The notification indicates that Bank of America Corporation, as controlling entity, crossed below the threshold of 10% of Lakefront’s voting rights on October 2, 202
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced interim data from its Phase 1 clinical trial of ER-100 in three participants with open angle glaucoma (OAG). The data demonstrated that a single intravitreal administrati
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologou
IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026 Date: October 12 - 14, 2026 Location: Hard Rock Hotel, New York, NY Presentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce preliminary results from its preclinical study of MB-204 in the Shank3Δex13-16 mouse model , a model associated with Phelan-McDermid sy
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week PISCATAWAY, N.J. and SANTA CLARA, Calif. , Oct. 8, 2026 / PRNewswire / -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest , a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript s wet lab validation and data generation capabilities and NVIDIA s accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.
Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of Bio Usawa Biotech Botswana (Pty) Ltd, marking an important milestone in the company’s mission to build a self-sustaining biotechnology ecosystem across Africa and expand access to safe, effective, and affordable biologic medicines. The Botswana subsidiary expands Bio Usawa’s interna
Fibocom and Grid-OS Accelerate IoT Deployment at Scale in India at IMC 2026
NEW DELHI , Oct. 8, 2026 -- Fibocom, a leading global provider of wireless communication modules and AI solutions, is collaborating with India-based IoT ODM Grid-OS to advance smart payment and vehicle tracking applications in India. At IMC 2026, Grid-OS is showcasing a Payment Soundbox powered by Fibocom s LE270 LTE Cat 1 bis module , alongside two 4G Vehicle Trackers based on Fibocom s LE250 series LTE Cat 1 bis modules . India s IoT market is moving rapidly toward large-scale deployment. NPCI data shows that UPI transactions reached 24.51 billion in August 2026 , while growing applications such as vehicle tracking are creating increasingly diverse requirements for reliable connectivity, low power consumption and positioning capabilities.
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows: Session: Advances in Oncology Panel Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ET Location: NYY Room at the Hard Rock Hotel NYC Mr. Klemp will discuss Mo
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
Nature Communications publication provides new evidence that Vaccinex’s pepinemab may help reshape the tumor environment to support a coordinated immune attack on cancer, potentially complementing checkpoint inhibitors and other immunotherapies ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI
AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026
SAN FRANCISCO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced an oral presentation at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. The presentation will feature new data from AltruBio’s Phase 2a ASCEND UC2a trial (NCT06109441) evaluating its
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten
CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia
Key milestone marks transition of CHARM into a clinical stage company Initial data anticipated in 2027 LONDON – 7 October 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, today announces it has initiated dosing and fully enrolled the first cohort in its Phase I/II clinical trial of CHM-029 in patients with AML. This is the first example of a molecule designed usi
Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026
Company to engage with wound-care professionals and meet with existing and prospective distribution partners WINNIPEG, Manitoba, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will attend the Symposium on Advanced Wound Care (“SAWC”) Fall 2026, taking place October 15–18, 2026, in Las Vegas, Nevada. O
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today provided an update on its strategy and progress to implement a suite of U.S. Food and Drug Administration (FDA) aligned New Approach Methodologies (NAMs) acr
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced the successful closing of a $150 million Series B financing. The financing was co-led by Nextech Invest and Norwest
MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence
Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 ( NCT05534269 ), demonstrating durable, sustained and clinically relevant bladder health benefits in patients treated with its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy for female stress urinary incontinence (SUI). SUI represents a high unmet
PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
PARIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized gene therapies with minimally invasive delivery technology, has presented further data from its PST-611 phase I clinical trial (CT1) in patients with advanced dry age-related macular degeneration (AMD), known as geographic atrophy (GA), in an oral presentation at the European Society of Retina Specialists’ 26th Euretina Congress, held 1-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
DUBAI, United Arab Emirates, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Microdomain Science connects differentiated assets across personalized immuno-oncology, acellular biotechnology, MedTech and precision nutrition as OGRD Alliance expands international market access, asset-specific licensing, commercialization and strategic-capital initiatives. OGRD Alliance L.L.C-FZ announced a new phase in the international development of PLPC Platform following the public listing with Singapore’s Health Sciences Au
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract developmen
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50 th Anniversary La Jolla Immunology Conference , taking place Oct
Acquisition of Own Shares
Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 28, 2026, and October 02, 2026, it has repurchased 117,437 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors
WATERTOWN, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Michael Landsittel to its Board of Directors. “We are delighted to welcome Michael to the Remix Board of Directors,” said Pete Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. “His proven track record of
INmune Bio to Attend the 2026 Maxim Growth Summit
BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. INmune Bio
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasd
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC) MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) , a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing throu
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NAS
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027 CAMBRIDGE, Mass.,, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company’s E
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for smal